BioInsights - Immuno-oncology CMC aspects

Immuno-oncology CMC aspects

Immuno-Oncology Insights 2021; 2(6), 361–362

10.18609/ioi.2021.045

Published: 6 December 2021
Foreword
Anurag Khetan, PhD

Anurag Khetan heads the Global Upstream and Cell Line Development area of Biologics Development in Bristol-Myers Squibb based in New Jersey in USA.  His end-to-end team interfaces with Discovery and Manufacturing and carries out process development of biologics and viral gene therapy programs ranging from molecular biology and analytics, cell line development, and upstream process development. Anurag has a BTech in Chemical Engineering from Indian Institute of Technology, Delhi and a PhD from the Department of Chemical engineering at the University of Minnesota. Anurag has had sustained contributions over nearly two decades in the biotechnology industry at Merck, Biogen, Boehringer Ingelheim and BMS in areas ranging from early and late process development, post-approval development, manufacturing support, and GMP manufacturing.